Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al.|The Lancet|2023Cited by 181
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben A. Mesa, Srđan Verstovšek, Claire Harrison et al.|Leukemia|2022Cited by 63
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trialsSrđan Verstovšek, Claire Harrison, Ruben A. Mesa et al.|Blood Advances|2023Cited by 48
Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipientsBetty K. Hamilton, Navneet S. Majhail, Aaron T. Gerds et al.|Bone Marrow Transplantation|2015Cited by 32